Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713894 | 0.96 | S1PR4 (0.40) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| Methane SCHEMBL4713877 | 0.95 | S1PR4 (0.39) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL8560840 | 0.82 | KMT2A (0.46) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL5659597 | 0.78 | ALDH1A1 (0.50) | NPC1KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL27744819 | 0.75 | NPC1 (0.40) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL29903448 | 0.74 | KMT2A (0.41) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL3167072 | 0.74 | KMT2A (0.41) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL27873051 | 0.74 | KMT2A (0.41) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL8603295 | 0.74 | NPC1 (0.39) | NPC1S1PR4KMT2AMEN1ALDH1A1 | |
| SCHEMBL3846725 | 0.73 | TDP1 (0.50) | NPC1KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641423-B1 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7476665-B2 | Benzodiazepine CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1641423-A4 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2007-05-17 | — | — | US | disclosed |
| CN-1842526-A | Benzodiazepine CGRP receptor antagonists | MERCK & CO INC (US) | 2006-10-04 | — | — | CN | disclosed |
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
| EP-1641423-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005013894-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | NPY1R, NPY2R, CCKBR | NPC1 1342/4885S1PR4 846/4885KMT2A 2267/4885 |
| US-20070111204-A1 | Methods for detecting nucleic acid variations | POLN, LIG4, NCL | NPC1 2560/4885S1PR4 4272/4885KMT2A 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.